Erasca (ERAS): Analysts See +60% Upside Potential to the $24 Target

Key Takeaways

• The central price target of $24 is the arithmetic mean of 10 verified analyst price targets reviewed for Erasca, with a current range of roughly $20 to $33.
• With the stock trading near $15, reaching $24 implies an upside of about 60%, a very large move that is nonetheless consistent with the stock's own 52-week range of roughly $2.11 to $24.28.
• Bullish targets cluster at $22–$33 (J.P. Morgan, Stifel, Jefferies, H.C. Wainwright, Piper Sandler), while more cautious views sit at $20–$21 (BofA Securities, Morgan Stanley, Guggenheim).
• The strongest support comes from the pan-RAS clinical program ERAS-0015, its Fast Track designation, and a roughly $632 million mid-2026 raise that extends the cash runway.
• The biggest risks are binary clinical-readout risk, a disclosure-related legal overhang, intensifying competition in the RAS space, and a rich valuation for a pre-revenue company.
• You can find more detail on this ticker's Major News, Today's Price Move, Forecast, and Earnings on dedicated pages.
• Explore Trending AI Robots to see AI-driven trading strategies across thousands of stocks and ETFs.

Analyst Price Targets and the Consensus View

Erasca, Inc. (ERAS) is a clinical-stage precision oncology company focused on RAS/MAPK pathway-driven cancers, headquartered in San Diego and founded in 2018. The $24 central target reflects the arithmetic mean of 10 verified analyst price targets issued from mid-2026 onward, spanning roughly $20 to $33. It is a calculated average, not an official published consensus. Views are unusually split. At the optimistic end, J.P. Morgan carries a $33 target and Stifel sits at $30, both Buy-rated, while Jefferies ($24), H.C. Wainwright ($22), Piper Sandler ($22), and Mizuho ($26) remain constructive. At the cautious end, Morgan Stanley ($21) and Guggenheim ($21) hold the stock, and BofA Securities ($20) rates it Neutral. The roughly 65% gap between the lowest and highest targets reflects genuine disagreement over how ERAS-0015, the company's lead pan-RAS molecular glue degrader, will fare in registration-enabling trials. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

Current Market Position and the Path Toward the Target

The stock has traded in the mid-teens, with recent closes ranging between roughly $14.35 and $15.12, and a market capitalization near $5 billion. That context is important: ERAS has already rallied dramatically, up roughly 300% year to date and more than 500% over the trailing year, after sitting near $2 a year ago. Reaching $24 therefore requires a further gain of about 60% from current levels — a very large move even by biotech standards. The path would most likely hinge on positive, durable clinical data from ERAS-0015 across pancreatic and lung cancer studies and on progress toward pivotal trials, rather than on near-term earnings, since the company remains pre-revenue with negative EPS (earnings per share).

What Could Support a Move Toward the Target

• ERAS-0015 has received FDA Fast Track designation, and management has reported encouraging early efficacy and tolerability signals relative to approved pan-RAS competitors.
• A roughly $632 million equity raise in July 2026 extended the cash runway into at least the second half of 2028, reducing near-term dilution risk.
• A clinical collaboration pairing ERAS-0015 with Merck's pembrolizumab (Keytruda) supports a combination strategy in first-line lung cancer.
• Multiple analysts raised price targets throughout 2026 as data momentum and strategic partnerships expanded the perceived opportunity.

What Could Prevent the Target From Being Reached

• Clinical programs are binary; disappointing efficacy or safety data could compress the multiple sharply.
• A disclosure-related legal probe into how management described risks around ERAS-0015 adds an overhang and execution uncertainty.
• Competition is intensifying, including Revolution Medicines' already-approved pan-RAS therapy daraxonrasib and other allele-specific KRAS programs.
• The valuation is demanding for a company with no marketed products, trading at a price-to-book multiple far above the biotech average.

Technical Levels and Market Structure

The 52-week high near $24.28 stands as a meaningful resistance level that also happens to sit almost exactly at the central target. After that peak, the stock pulled back into the low-to-mid teens, with recent consolidation near $13–$15 acting as a support zone. Intermediate resistance sits near the $18–$20 range, where several analyst targets cluster and where the shares spent time earlier in 2026. The wide $2.11-to-$24.28 range underscores how volatile the stock's structure remains. From what I see, these levels remain worth watching closely.

Time Horizon and What Investors Should Monitor

Analyst price targets generally reflect a research horizon of about 12 months, though individual analysts apply different assumptions. Investors should watch ERAS-0015 data readouts and pivotal-trial initiations, the resolution or escalation of the disclosure probe, updates to the Merck combination program, and any further analyst target revisions. Quarterly results and cash-burn updates also matter, given that the company is not yet generating product revenue.

Using Tickeron AI Tools for Ongoing Monitoring

In my research process, I frequently rely on Tickeron's AI Daily Buy/Sell Signals to apply artificial intelligence that continuously monitors thousands of stocks and ETFs. These signals generate Buy, Sell, or Hold recommendations based on shifting market conditions, technical behavior, and AI-driven analysis. This approach helps me spot changing trends, identify new opportunities, and track existing positions more efficiently than reviewing charts manually. Traders looking for a more systematic edge in fast-moving markets may find these AI-generated signals useful for their own workflow.

Final Assessment

The question of whether Erasca can reach $24 is best understood as a question about clinical execution rather than valuation mechanics. The $24 central target, an average of 10 analyst price targets ranging from $20 to $33, implies a roughly 60% advance from current levels and coincides closely with the stock's prior 52-week high. Support comes from a derisked balance sheet, Fast Track status, and early ERAS-0015 data; obstacles include binary trial risk, a legal overhang, mounting competition, and a rich valuation. Analysts themselves remain divided between high Buy-rated targets and cautious Hold-rated targets, reflecting genuine uncertainty. Whether ERAS reaches $24 will depend most on whether the lead program's clinical data continue to validate the thesis through pivotal-stage development. No outcome is guaranteed.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Contributor

Sergey Savastiouk|Expert

Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.

Notable companies

Industry description

Market Cap

High and low price notable news

Volume